Clinical trials: ER Positive
Breast Cancer
Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- MINDACT (NCT00433589)
- Testing
- anthracycline-based, docetaxel and capecitabine, tamoxifen
- Where
- Netherlands
- Volunteers
- 6,600 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Early-stage Breast Cancer, Carbohydrate Engorgement
Breast Cancer Diet Intervention Study
The investigators have already proven that Mitotic Activity Index (MAI)is the most robust measure of proliferation in breast cancer tissue.
- Conditions
- Early-stage Breast Cancer, Carbohydrate Engorgement, Proliferation, Insulin Resistance
- Trial name
- BCDIS (NCT03886389)
- Testing
- PreOP
- Volunteers
- 80 people
- Sponsor
- Helse Stavanger HF
Female Breast Cancer
Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer
The purpose of this study is to evaluate the role of patients' response expectations for nocebo side effects, quality of life and adherence during adjuvant endocrine treatment (AET).
- Trial name
- NCT02088710
- Testing
- Enhanced information about endocrine therapy
- Where
- Germany
- Volunteers
- 138 people
- Sponsor
- Philipps University Marburg
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
This phase II trial tests the effectiveness of cannabidiol (CBD) plant extract (BRC-001) in improving joint stiffness and pain (arthralgia) in women with breast cancer taking aromatase inhibitors (AIs).
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
- Trial name
- NCT06538389
- Testing
- Biospecimen Collection, BRC-001, Questionnaire Administration
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer
This is a prospective, open-label, single-center, randomized controlled Phase II clinical study aimed at evaluating the efficacy and safety of neoadjuvant imlunestrant combined with abemaciclib guided by the Ki67 index after 2…
- Trial name
- NCT07410559
- Testing
- Imlunestrant + abemaciclib, (dd)EC*4-T*4
- Where
- China
- Volunteers
- 189 people
- Sponsor
- Fudan University
Breast Cancer, Invasive Breast Cancer
Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC
This study is investigational and is not designed to treat cancer. In other words, the study drug, entinostat, is not being given to treat cancer.
- Conditions
- Breast Cancer, Invasive Breast Cancer, ER-Negative PR-Negative HER2-Negative Breast Cancer
- Trial name
- NCT03361800
- Testing
- Entinostat
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Early Breast Cancer
Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients
Evaluating the safety, tolerability and efficacy of Aromasin® when used in routine clinical practice, evaluating adherence to prescribed Aromasin® treatment and to understand reasons for early discontinuation.
- Trial name
- NCT01155063
- Testing
- Aromasin (exemestane)
- Volunteers
- 89 people
- Sponsor
- Pfizer
Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) breast cancer.
- Conditions
- Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Breast Cancer
- Trial name
- CAPELA (NCT07222215)
- Testing
- Capecitabine, Elacestrant
- Where
- United States
- Volunteers
- 297 people
- Sponsor
- Kristina A. Fanucci
Breast Cancer, Triple Negative Breast Cancer
Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)
This is a single centre Window-of-Opportunity trial investigating the efficacy and feasibility of short term imatinib in patients with newly diagnosed triple negative breast cancer (TNBC) planned for surgery, with tumours ≥ 15…
- Trial name
- I-CONIC (NCT05722795)
- Testing
- Imatinib 400 MG Oral Tablet
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Vastra Gotaland Region
Breast Cancer
Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
This research study is studying a drug called Neratinib with and without Fulvestrant as possible treatments for HER2-positive breast cancer . The interventions involved in this study are: Neratinib and Fulvestrant Neratinib alone
- Trial name
- NCT03289039
- Testing
- Neratinib, Fulvestrant
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897065
- Testing
- microarray analysis, polymerase chain reaction, protein expression analysis
- Where
- United States
- Volunteers
- 957 people
- Sponsor
- Massachusetts General Hospital
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
This phase I/II trial studies the side effects and best dose of hydroxychloroquine when given together with palbociclib and letrozole before surgery in treating patients with estrogen receptor positive, HER2 negative breast…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT03774472
- Testing
- Hydroxychloroquine, Letrozole, Palbociclib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer Female
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
This clinical trial is designed to be a multi-center prospective, parallel-controlled Phase III clinical study. In this study, the efficacy of tamoxifen versus toremifene shall be compared in CYP2D6 intermediate/poor metabolizers…
- Trial name
- NCT03351062
- Testing
- Tamoxifen, Toremifene
- Where
- 21 sites in China
- Volunteers
- 844 people
- Sponsor
- Chinese Anti-Cancer Association
Breast Cancer
Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, methotrexate, and prednisolone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00687648
- Testing
- anastrozole, cyclophosphamide, exemestane
- Where
- Singapore
- Volunteers
- 70 people
- Sponsor
- National Cancer Centre, Singapore
Breast Neoplasms
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer.
- Trial name
- preEMBER (NCT07287098)
- Testing
- Imlunestrant, Goserelin, Tamoxifen 20 mg
- Where
- 87 sites in United States, Belgium and 5 more
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
The study drug cabozantinib works by inhibiting several different proteins which are believed to be involved in breast cancer tumor growth, its ability to spread, and its ability to form new blood vessels.
- Trial name
- NCT01441947
- Testing
- Cabozantinib, Fulvestrant
- Where
- 4 sites in United States
- Volunteers
- 68 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer
Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib
This is a prospective, randomized, open-label, multicenter phase III study to explore chemotherapy omission in ER+/HER2-endocrine-sensitive breast cancer with 1-3 positive lymph nodes receiving extended (3 year) adjuvant…
- Trial name
- Rainbow (NCT06341621)
- Testing
- 3-year abemaciclib without chemo, treatment of physician's choice
- Where
- China
- Volunteers
- 1,900 people
- Sponsor
- Fudan University
ER-Positive HER2-Negative Breast Cancer
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in…
- Trial name
- SERENA-6 (NCT04964934)
- Testing
- AZD9833, Anastrozole, Letrozole
- Where
- 264 sites in United States, Australia and 21 more
- Volunteers
- 315 people
- Sponsor
- AstraZeneca
Breast Cancer
Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study
The purpose of this study is to compare the changes in a proliferation biomarker in subjects receiving Anastrozole or Anastrozole/ZD1839 combination.
- Trial name
- NCT00255463
- Testing
- Anastrazole, Gefitinib
- Where
- 34 sites in Czechia, France and 5 more
- Volunteers
- 185 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer, Estrogen-receptor-positive Breast Cancer
The FEMA Study: Feasibility of Exercise in Patients With Metastatic Breast Cancer and Adiposity
The goal of this clinical trial is to test a physical activity program in patients with metastatic breast cancer and overweight receiving endocrine-based treatment.
- Conditions
- Metastatic Breast Cancer, Estrogen-receptor-positive Breast Cancer, Adiposity
- Trial name
- NCT06343987
- Testing
- Physical Activity
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- Aarhus University Hospital